Pauline Lejault’s Post

Exciting News from Celularity! 🎉 Over the weekend, Celularity showcased an in vivo study of PT-CD16 at the 2024 ASCO Annual Meeting. PT-CD16 is a genetically modified allogeneic cell therapy derived from human placental circulating T (P-T) cells. Celularity has adopted a “Universal Receptor” strategy to create a platform of genetically modified T-cells expressing a proprietary CD16 receptor. The versatility of this approach allows a single drug product to be manufactured and combined with a variety of approved antibodies, to target multiple tumor antigens across a wide range of cancers (solid and hematological) and other conditions. Discover more about our study and presentation through the links below. 👇 https://lnkd.in/eeXQCikj https://lnkd.in/eX2ks6GG 👏 to Kristina Tess, Mansour DJEDAINI, Natalia Ruggeri Barbaro, Chenfei Huang, PhD, Joseph Gleason, Shengchen Lin, Dr. Adrian Kilcoyne MD MPH MBA, John Fitzgerald, and the entire T-cell Therapy Research Team! #Celularity #ASCO2024 #CellTherapy #CancerResearch #Innovation 👩🏼🔬🧪

Making Sense of Complex Genomic Data with Advanced Insights! As clinical NGS testing expands with new targeted therapies and gene panels, the challenge of quality variant classification grows too. Discover how Velsera is addressing this with our Clinical Genomics Workspace and Knowledgebase—designed to streamline complex workflows and provide rapid, accurate variant interpretations. Check out our tech note for an in-depth look at how the Knowledgebase empowers somatic cancer biomarker reporting! Visit our page to learn more: https://lnkd.in/gCvNNKHw #Eraofvelsera #ClinicalGenomics #NGS #PrecisionMedicine #VariantInterpretation

At BIO2024 Convention? Don't miss Biotech Primer's informative Cell Therapy Primer, happening today! Date: Wednesday, June 5, 2024 Time: 1:45 - 2:45 PM Location: Room 23BC Join Kevin Curran, PhD, for an engaging overview of cell therapies. Discover how living cells are optimized and reintroduced to treat diseases, including innovative CAR-T therapy and gene editing technologies like CRISPR/CAS9. The session concludes with a case study on Casgevy for Sickle Cell Disease. Highlights: • Cell Therapy Basics: Understanding the process of optimizing and reintroducing living cells to treat diseases. • CAR-T Therapy: Insights into inserting synthetic genes to target and destroy cancer cells. • Gene Editing Technologies: Combining cell therapy with CRISPR/CAS9 to address genetic disorders. • Case Study: Overview of the recently approved Casgevy for Sickle Cell Disease. We hope to see you there! #BiotechPrimer #BIO2024 #BiotechInnovation

At BIO2024 Convention? Don't miss Biotech Primer's informative Cell Therapy Primer, happening today! Date: Wednesday, June 5, 2024 Time: 1:45 - 2:45 PM Location: Room 23BC Join Kevin Curran, PhD, for an engaging overview of cell therapies. Discover how living cells are optimized and reintroduced to treat diseases, including innovative CAR-T therapy and gene editing technologies like CRISPR/CAS9. The session concludes with a case study on Casgevy for Sickle Cell Disease. Highlights: • Cell Therapy Basics: Understanding the process of optimizing and reintroducing living cells to treat diseases. • CAR-T Therapy: Insights into inserting synthetic genes to target and destroy cancer cells. • Gene Editing Technologies: Combining cell therapy with CRISPR/CAS9 to address genetic disorders. • Case Study: Overview of the recently approved Casgevy for Sickle Cell Disease. We hope to see you there! #BiotechPrimer #BIO2024 #BiotechInnovation

✨Analyzing a patient's healthy cells and tumor cells in-depth requires a combination of sequencing strategies. We typically use Whole Exome Sequencing or Whole Genome Sequencing on both sample types, along with #RNA Sequencing on the tumor samples. ☑ This approach allows us to examine gene expression patterns and understand the genetic and transcriptional landscape of the tumor. Additionally, we may employ long-read sequencing to enhance the accuracy of sequencing repetitive regions, ensuring precise tumor characterization. 💡 This combined sequencing approach is a key part of our neoantigen discovery workflow. To learn more about this workflow, check out our article ( https://lnkd.in/dqF6ZRxs ) and request a copy of our case study with #myNEO Therapeutics. #WGS #neoantigen #health Stefanie Klaver-Flores, PhD | Mirian Daniela Obrador | Raymond Egging

📌 The integrated molecular and histological analysis of esophageal squamous cell carcinoma Jiang et al. performed genomic-transcriptomic characterizations and AI-aided histopathological image analysis of 120 Chinese esophageal squamous cell carcinoma (ESCC) patients.   Key findings 🔸 Categorizing ESCC into differentiated, metabolic, immunogenic and stemness subtypes 🔸 Poorest prognosis and downregulated immune activities in the stemness subtype with WFDC2, SFRP1, LGR6 and VWA2 gene expression 🔸 Overexpression of natural killer cell markers XCL1 and CD160 as immune evasion in ESCC 🔸 XCL1 expression affecting the sensitivity of ESCC cells to common chemotherapy drugs. ➡️ More details: https://lnkd.in/eFqx9hwV #spatialomics #spatialbiology #singlecellanalysis #singlecell #ZhengzhouUniversity

Cell, gene, and advanced therapies (CGATs), such as radioligand therapies and personalized cancer vaccines (PCVs), have the potential to revolutionize the treatment landscape and even cure previously incurable diseases. This is incredibly exciting for all of us! Despite the uniqueness of cell, gene, and other advanced therapies like PCVs and radioligand therapies, there are many commonalities in the challenges that need to be addressed to bring scale and maximize the patient impact. We invite you to join our CGAT experts, Sankalp Sethi, Arvind Kumar, and Christopher Wong, as they explore how connected digital systems tailored for the complex CGAT journey can create a comprehensive ecosystem. This ecosystem will streamline interactions and optimize outcomes across the patient’s care continuum. #cellandgenetherapy #radiotherapy #advancedtherapies We look forward to seeing you on August 28th! Click the link to sign up today: https://lnkd.in/efZ8nzfn

https://lnkd.in/dCDqD8Ph Cell, gene, and advanced therapies is rapidly evolving, driven by groundbreaking scientific discoveries and the promise of transformative treatments for a wide range of diseases. As these innovative therapies continue to advance, the integration of digital technologies is poised to play a pivotal role in unlocking their full potential. By harnessing the power of data-driven insights embedded within digital platforms can enable seamless patient engagement, remote monitoring, and personalized care plans, ultimately improving patient outcomes and experiences.

Our Selective Organ Targeting (SORT) next-generation lipid nanoparticle (LNP) platform has been a cornerstone in our research efforts to restore ciliary function in  the lungs of people with PCD caused by pathogenic mutations in the DNAI1 gene. Developed in collaboration with the University of North Carolina at Chapel Hill and UT Southwestern Medical Center, our mRNA-based therapy is optimized and formulated in SORT LNPs, which are engineered with a biochemically distinct fifth lipid to help the body “sort” and direct the LNPs to targeted cells and organs.  Preclinical data show that our DNAI1 mRNA leads to DNAI1 protein production in target cells and can rescue ciliary function. In cell-based knock-out models, the restored ciliary function persisted for weeks after the last treatment. Through continued research, we aim to develop a much-needed therapy for people with PCD and highlight the vast potential of mRNA-based therapies for other rare and common genetic diseases. Learn more about this project below: https://lnkd.in/gyjDRmje

🌟 We are delighted to introduce our new ready-to-use assays: the P300 and CBP Histone Acetyltransferase (HAT) Lytic Detection Assays, both with a rapid turnaround time of just 3 working days! Our assays provide robust and precise measurement of P300/CBP protein levels in cell models, offering valuable insights when assessing the effectiveness of targeted protein degradation (TPD) agents. By employing our developed H1299-P300-HiBiT and H1299-HiBiT-CBP cell lines, we have enhanced the assay's performance for screening with P300/CBP PROTACs, empowering researchers in their quest to unravel cancer mechanisms and explore potential therapeutic avenues. As critical players in gene regulation, cell proliferation, and differentiation, the histone acetyltransferase activities of P300 and CBP are fundamental to cellular function, with cancer being a primary and pressing concern. #P300 #CBP #HAT #TPD #PROTAC #celllinedevelopment #cancertherapy #drugdiscovery